AU2020261515B2 - Compositions and methods for use of cannabinoids for neuroprotection - Google Patents

Compositions and methods for use of cannabinoids for neuroprotection

Info

Publication number
AU2020261515B2
AU2020261515B2 AU2020261515A AU2020261515A AU2020261515B2 AU 2020261515 B2 AU2020261515 B2 AU 2020261515B2 AU 2020261515 A AU2020261515 A AU 2020261515A AU 2020261515 A AU2020261515 A AU 2020261515A AU 2020261515 B2 AU2020261515 B2 AU 2020261515B2
Authority
AU
Australia
Prior art keywords
neuroprotective
compound
neurodegeneration
neuroprotective compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020261515A
Other languages
English (en)
Other versions
AU2020261515A1 (en
Inventor
Eric Hsu
Ujendra Kumar
Rishi Kumar SOMVANSHI
Shenglong Zou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inmed Pharmaceuticals Inc
Original Assignee
Inmed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc filed Critical Inmed Pharmaceuticals Inc
Publication of AU2020261515A1 publication Critical patent/AU2020261515A1/en
Application granted granted Critical
Publication of AU2020261515B2 publication Critical patent/AU2020261515B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020261515A 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection Active AU2020261515B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
US62/838,216 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (2)

Publication Number Publication Date
AU2020261515A1 AU2020261515A1 (en) 2021-11-18
AU2020261515B2 true AU2020261515B2 (en) 2025-10-23

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020261515A Active AU2020261515B2 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Country Status (11)

Country Link
US (1) US20230043428A1 (https=)
EP (1) EP3958856A4 (https=)
JP (1) JP7633179B2 (https=)
KR (1) KR20220080045A (https=)
CN (1) CN114007603A (https=)
AU (1) AU2020261515B2 (https=)
CA (1) CA3134764A1 (https=)
IL (1) IL287536B2 (https=)
MX (1) MX2021012960A (https=)
SG (1) SG11202111809XA (https=)
WO (1) WO2020215164A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
WO2024091653A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism
WO2024148117A2 (en) * 2023-01-04 2024-07-11 Florascience Inc. Methods of treating neurodegenerative diseases or conditions
WO2025090133A1 (en) * 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180098948A1 (en) * 2016-10-11 2018-04-12 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
WO2018205022A1 (en) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2640379A4 (en) * 2010-11-18 2014-08-13 Pier Pharmaceuticals LOW DOSED CANNABINOIDARY MEDICINES
BR122021018502B1 (pt) * 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
US20160282371A1 (en) * 2015-03-28 2016-09-29 Quantalytical Labs Inc. Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180098948A1 (en) * 2016-10-11 2018-04-12 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
WO2018205022A1 (en) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Elsohly, M.A. et al., 'Cannabinoids in glaucoma: a primary screening procedure', Journal of Clinical Pharmacology. 1981, vol.21, pages 472S-478S *
Kabiri, M. et al., 'A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery', Drug Delivery and Translational Research. 2018, vol.8, pages 484-495 *

Also Published As

Publication number Publication date
IL287536A (en) 2021-12-01
AU2020261515A1 (en) 2021-11-18
WO2020215164A1 (en) 2020-10-29
EP3958856A4 (en) 2023-01-25
IL287536B2 (en) 2026-03-01
US20230043428A1 (en) 2023-02-09
SG11202111809XA (en) 2021-11-29
IL287536B1 (en) 2025-11-01
JP2022530471A (ja) 2022-06-29
JP7633179B2 (ja) 2025-02-19
KR20220080045A (ko) 2022-06-14
EP3958856A1 (en) 2022-03-02
CN114007603A (zh) 2022-02-01
MX2021012960A (es) 2022-01-04
CA3134764A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
AU2020261515B2 (en) Compositions and methods for use of cannabinoids for neuroprotection
JP6060168B2 (ja) レバミピドと涙液保持作用を有する薬剤からなる前眼部疾患治療剤
WO2008136034A2 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
JP2010514733A (ja) 高眼圧症の治療のためのイソソルビドモノニトレート誘導体
US7825134B2 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
WO2005055926A2 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US20230381205A1 (en) Compositions and methods for treating neuronal disorders with cannabinoids
US20240261273A1 (en) Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
JP7834370B2 (ja) 緑内障の治療のためのカルパイン－２選択的阻害剤化合物
EP1280528B1 (en) R-eliprodil for treating glaucoma
AU778148B2 (en) 2-aminotetralin derivatives for the therapy of glaucoma
WO2025090133A1 (en) Compositions and methods for use of cannabinol compounds in neuroprotection
US20080318939A1 (en) Methods for treating ophthalmic disorders
AU2025217391A1 (en) Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
WO2025090587A1 (en) Cannabinoids compounds and their use in the treatment of neuronal disorders
JPWO2002051431A1 (ja) 網膜虚血に基づく疾患の治療および／または予防剤
Sgambellone et al. Special Focus on Glaucoma
Kobayashi et al. 152. Neuroprotection Organizing Section: PH Contributing Section: RC
US20030212107A1 (en) R-reliprodil for treating glaucoma
ZA200604402B (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)